Discordant Trial Results Among Issues FDA Bringing To Advisory Panel Review Of Novartis' Afinitor

The change in endpoints for the two pivotal studies in neuroendocrine tumors and the fact that they don't support each other will fuel the Oncologic Drugs Advisory Committee discussion of the new indication for everolimus.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet